Is Incyte Corporation (INCY) overvalued? · P/E 14, rev $5.14B
Incyte Corporation (INCY) is a biotechnology company listed on US.
This page asks whether Incyte Corporation (INCY) looks expensive on cached numbers — not a short thesis.
Latest reported INCY revenue for 2025-12-31 was $5.14B. Net income was $1.29B. Revenue was up 21.2% from 2024-12-31 to 2025-12-31. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
INCY currently screens at market cap $20.45B and trailing P/E 14.5. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next INCY 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the INCY stock page for the full model, not this heading.
Not investment advice.